Upstaging Risk and Prognosis of Clinical T2-3N0M0 Esophageal Squamous Cell Carcinoma Patients after a Curative...

Neoadjuvant chemoradiation therapy (nCRT) has survival benefits for patients with cT1N1 or cT2-3N0-1 esophageal squamous cell carcinoma (ESCC), but heterogeneous disease behavior has been observed in node-negative tumors. This study aimed to investigate the risk of upstaging and the efficacy of upfront esophagectomy compared with nCRT followed by surgery in patients with cT2-3N0 ESCC.

ESCC patients treated at Taipei Veterans General Hospital, Taiwan, between January 2010 and December 2022 were retrospectively reviewed. Patients who underwent upfront surgery (n=72) and those who received neoadjuvant therapy (n=36) were included in this analysis on an intention-to-treat basis after propensity score matching. Comparisons of TNM (tumor, node, and metastasis) classification shifts between patients who underwent upfront surgery and those who received neoadjuvant therapy, as well as primary outcomes including overall survival (OS) and recurrence-free survival (RFS), were analyzed.

Among patients who underwent upfront surgery, 6 (16.7%) in the cT2 group and 10 (27.8%) in the cT3 group had occult lymph node (LN) metastasis. Most patients (77.4%) who received neoadjuvant therapy experienced downstaging; however, there were no significant differences in OS (5-year OS: 53.8% vs. 51.6%, p=0.666) or RFS (5-year RFS: 48.6% vs. 44.8%, p=0.864) compared with upfront surgery. No significant differences were observed before propensity score matching for either OS (p=0.809) or RFS (p=0.856).

Upfront esophagectomy in patients with cT2-3N0 ESCC provides comparable survival outcomes, despite the higher risk of upstaging and occult LN metastasis.